At PamGene we are dedicated to support physicians and scientists in finding solutions and answers to improve and optimize patient treatment and understand diseases. Our multiplex kinase activity profiling technology reveals the bigger picture of cellular signaling and provides mechanistic insights needed to fully understand diseases and cell alterations.
Dr. Jan Groen is Chief Executive Officer of Intravacc, a vaccine development company. Previously he was CEO of MDxHealth, a Euronext listed genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers.
Dr. Groen’s career spans over many years in clinical diagnostics including new product development and commercialization of CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA. He was previously the President and COO of Agendia, responsible for their US and European diagnostic operations, respectively. He is also co-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, and Akzo-Nobel. Dr. Groen has had board mandates in several diagnostic companies.
Currently he serves as chairman of the board of Cergentis, and has board positions at Novigenix SA, Angle plc, SPLMedical B.V. and Destination Genomics. Dr. Groen holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.
Prof. Bob Pinedo was the founder and Chairman of the Board of the VUmc Cancer Center Amsterdam where research and patient care are closely interwoven. He retired in 2008 as Professor of Medical Oncology at the VU University Medical Center.
He has received many international awards including the prestigious Dr Josef Steiner Cancer Research Foundation Award (1995), the NOW Spinoza Price (1997) and the David A. Karnofsky Memorial Award of the American Society of Clinical Oncology (2014). In 2008 Dr. Pinedo has been decorated by H.M. Queen Beatrix of the Netherlands as Knight in the Order of the Netherlands Lion. He is a member of the Royal Dutch Academy of Science and Arts and has published over 700 research articles in peer-reviewed international journals.
Prof. Dr. Bob Pinedo, is acting as Visiting Professor at the Johns Hopkins University (Baltimore, USA) and Technical University Twente since 2008. He serves as Chairman of the Board of the Caribbean Prevention Center in Curaçao is Chairman of the International Advisory Board of the Vrije University Imaging Center. Professor Pinedo is founder and advisor to Qurin Diagnostics and consultant to a number of start-ups since 2018.
Dr. Wiersma is fully qualified as a notified body auditor for all the Medical Device Directive (MDD 93/42/EEC); Medical device regulation (MDR EU 2017/745) and the In Vitro Diagnostic Device Directive (IVDD 98/79/EC) and In Vitro Diagnostic Device Regulation (IVDR 2017/746). After working for 8 years at a multinational Pharmaceutical company (Organon), first as scientific researcher and later as a Strategist in Strategy and Business Development department, she started to work for a Notified Body in the field of Medical Devices and In Vitro Diagnostic Medical Devices for 6.5 years. As of 2013 until 2015 she was part time QA/RA director and part of management team of an IVD company in the Netherlands.
Since March 2015 dr. Wiersma is board member of the RAPS Netherlands Chapter. RAPS is the Regulatory Affairs Professional Society. As of March 2017, she is the chair of the board of the RAPS Netherlands Chapter. And as of September 2017, she is a member of the REC as well (RAPS European Council). Dr. Anja Wiersma, is a medical biologist by training with a PhD in the NeuroPharmacological – Behavioural – Physiology field.
Dr. Groen’s career spans over many years in clinical diagnostics including new product development and commercialization of CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA. He was previously the President and COO of Agendia, responsible for their US and European diagnostic operations, respectively. He is also co-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, and Akzo-Nobel. Dr. Groen has had board mandates in several diagnostic companies.
Currently he serves as chairman of the board of Cergentis, and has board positions at Novigenix SA, Angle plc, SPLMedical B.V. and Destination Genomics. Dr. Groen holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.
He has received many international awards including the prestigious Dr Josef Steiner Cancer Research Foundation Award (1995), the NOW Spinoza Price (1997) and the David A. Karnofsky Memorial Award of the American Society of Clinical Oncology (2014). In 2008 Dr. Pinedo has been decorated by H.M. Queen Beatrix of the Netherlands as Knight in the Order of the Netherlands Lion. He is a member of the Royal Dutch Academy of Science and Arts and has published over 700 research articles in peer-reviewed international journals.
Prof. Dr. Bob Pinedo, is acting as Visiting Professor at the Johns Hopkins University (Baltimore, USA) and Technical University Twente since 2008. He serves as Chairman of the Board of the Caribbean Prevention Center in Curaçao is Chairman of the International Advisory Board of the Vrije University Imaging Center. Professor Pinedo is founder and advisor to Qurin Diagnostics and consultant to a number of start-ups since 2018.
Dr. Wiersma is fully qualified as a notified body auditor for all the Medical Device Directive (MDD 93/42/EEC); Medical device regulation (MDR EU 2017/745) and the In Vitro Diagnostic Device Directive (IVDD 98/79/EC) and In Vitro Diagnostic Device Regulation (IVDR 2017/746). After working for 8 years at a multinational Pharmaceutical company (Organon), first as scientific researcher and later as a Strategist in Strategy and Business Development department, she started to work for a Notified Body in the field of Medical Devices and In Vitro Diagnostic Medical Devices for 6.5 years. As of 2013 until 2015 she was part time QA/RA director and part of management team of an IVD company in the Netherlands.
Since March 2015 dr. Wiersma is board member of the RAPS Netherlands Chapter. RAPS is the Regulatory Affairs Professional Society. As of March 2017, she is the chair of the board of the RAPS Netherlands Chapter. And as of September 2017, she is a member of the REC as well (RAPS European Council). Dr. Anja Wiersma, is a medical biologist by training with a PhD in the NeuroPharmacological – Behavioural – Physiology field.